Benjamin A. Young was named program manager at the Marvin & Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center, where he will work with researchers to coordinate the institute’s basic, clinical, and population sciences research programs.
Baptist Health South Florida and the American Lung Association have partnered to raise awareness for lung cancer screenings through “Saved by the Scan,” a public service advertising campaign aimed at educating Americans about the low-dose CT scan available to those at high risk for the disease.
Mount Sinai Health System and BronxCare Health System have launched BronxCare Mount Sinai Comprehensive Cancer Care—a new comprehensive cancer facility in the Bronx.
A team from Roswell Park Comprehensive Cancer Center has identified the beta-adrenergic receptor (β-AR) as a driver of immune suppression and cancer growth in response to chronic stress, opening the possibility of targeting this receptor in cancer therapy and prevention.
University of Utah study finds risk of age-related diseases may be higher in younger B-NHL survivors
University of Utah researchers found that younger B-cell non-Hodgkin lymphoma (B-NHL) survivors had a higher relative risk of developing age-related diseases than older B-NHL survivors five years or more after cancer diagnosis.
The American Lung Association’s LUNG FORCE initiative released the 2021 Lung Health Barometer, a national survey that examines awareness, attitudes, and beliefs about lung health and lung cancer. This is the sixth year the survey has been conducted.
Researchers at Johns Hopkins Medicine and Italy’s Catholic University of the Sacred Heart medical school have shown that copper ions combined with disulfiram (DSF), a drug used for nearly 70 years as a treatment for alcoholism, may help kill and prevent the growth of medulloblastoma cancer cells in children.
FDA granted accelerated approval to Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase, who were previously treated with two or more tyrosine kinase inhibitors. FDA also approved Scemblix for adult patients with Ph+ CML in CP with the T315I mutation.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.For further information, contact the principal investigator listed.
Stanley Reimann was just one man, but in September 1930 he faced the daunting task of sustaining a fledgling research institute, which had started in 1921 in a makeshift lab above a hospital morgue, dedicated to unraveling the causes of cancer.
